raloxifene hydrochloride has been researched along with glyceryl behenate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aditya, N; Kathuria, H; Malekar, S; Ravi, PR; Vats, R | 1 |
| Kohli, K; Mangla, B; Neupane, YR; Singh, A; Sonali, LJ; Soni, NK | 1 |
| Ahmed, OAA; Aldawsari, HM; Alhakamy, NA; Badr-Eldin, SM; Fahmy, UA; Neamatallah, T; Okbazghi, SZ | 1 |
3 other study(ies) available for raloxifene hydrochloride and glyceryl behenate
| Article | Year |
|---|---|
Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism.
Topics: Administration, Oral; Animals; Chromatography, High Pressure Liquid; Drug Carriers; Drug Compounding; Drug Stability; Fatty Acids; Female; Nanoparticles; Particle Size; Poloxamer; Raloxifene Hydrochloride; Rats, Wistar; Selective Estrogen Receptor Modulators; Surface Properties; Tissue Distribution | 2014 |
Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Drug Carriers; Ethylene Glycols; Fatty Acids; Female; Humans; MCF-7 Cells; Nanostructures; Raloxifene Hydrochloride; Rats, Wistar; Selective Estrogen Receptor Modulators | 2020 |
Optimized semisolid self-nanoemulsifying system based on glyceryl behenate: A potential nanoplatform for enhancing antitumor activity of raloxifene hydrochloride in MCF-7 human breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Fatty Acids; Female; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Rats; Rats, Wistar | 2021 |